Blog

Maria Babak: Best of luck, CityU iGEM team

Maria (Masha) Babak/LinkedIn

Oct 25, 2024, 09:26

Maria Babak: Best of luck, CityU iGEM team

Maria Babak, Head of The Babak Lab, shared a post on LinkedIn by The Babak Lab, adding:

“Best of luck, CityU iGEM team!

Day 1 is just the beginning of an incredible journey! Your passion and dedication are already shining through, and I have no doubt you’ll make a lasting impact. Keep those ideas flowing and connections growing—you’ve got this!

Can’t wait to see what you’ll achieve. Go make us proud!”

Quoting The Babak Lab’s post:

“Day 1 at iGEM Competition: Off to a Great Start!

CityU iGEM first day in Paris has been nothing short of amazing! We’ve had the opportunity to meet so many brilliant minds from other iGEM teams and engage in some valuable scientific exchanges about each other’s projects. The diversity of ideas and passion for synthetic biology is truly inspiring!

It’s incredible to see how teams from all over the world are coming together to tackle global challenges. Can’t wait to dive even deeper into these conversations and collaborations throughout the competition!

Stay tuned for more updates as we continue this exciting journey!”

Jemma Arakelyan, Chief Executive Officer of The Institute of Cancer and Crisis, shared Maria Babak’s post. adding:

“So excited for the CityU iGEM team!

With Maria (Masha) Babak, PhD as their mentor, I believe they’ll bring home a Gold medal from Paris. Their hard work and passion for synthetic biology are inspiring. Let’s cheer them on—go team! You’ve got this!”

Maria Babak: Best of luck, CityU iGEM team

More posts featuring Maria Babak and Jemma Arakelyan.

Dr. Maria (Masha) Babak is the Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong. In November 2020, she joined the City University of Hong Kong as an assistant professor. Dr. Babak received the Graeme Hanson-AsBIC Early Career Award in 2022.

Her research interests are at the intersection of chemistry, biology, and medicine, with a focus on the discovery and preclinical development of anticancer drugs for resistant and aggressive cancers with limited treatment options, such as malignant pleural mesothelioma and brain metastases. She received the Yvonne Award by OncoDaily in the “mentorship” category.

Dr. Jemma Arakelyan is a medical oncologist and the Chief Executive Officer of The Institute of Cancer and Crisis. Under her leadership, the Institute is dedicated to raising awareness and providing support for cancer patients facing critical challenges, including those arising from war and pandemics.

Currently, she is pursuing her Ph.D. at the City University of Hong Kong, focusing on the development of new anticancer treatments and the mechanisms driving cancer progression.

In addition to her academic work, Dr. Arakelyan is actively involved in several scientific organizations, including the European School of Oncology (ESO), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). She also serves as an advisor at the Immune Oncology Research Institute, where they work closely on the clinical development of novel immunotherapeutic agents.